The board of directors of the US-listed company Enlivex Therapeutics has approved the purchase of 1 million dollars of BTC as reserve assets.

robot
Abstract generation in progress

PANews reported on November 21 that Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a US-listed company, announced yesterday that its board of directors approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy. Oren Hershkovitz, CEO of Enlivex, said, "With the continuous rise in demand for BTC and its increasing acceptance as a recognized Medium of Exchange, we believe that BTC will become a strong and diversified reserve asset for the company. With the recent approval of Bitcoin ETF and increasing support from institutional investors, we believe that BTC can provide the company with potential functional value storage and inflation hedging for standard currency." Enlivex is a clinical-stage macrophage reprogramming immunotherapy company, according to reports.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)